S. Singer

A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor.

M. Mihm, G. Dranoff, A. Sober, 1997, Human gene therapy.

A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed

Thomas C. Chen, A. Schönthal, Thomas C Chen, 2022, Frontiers in Oncology.

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

D. Neuberg, M. Mihm, F. Hodi, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.

D. Neuberg, M. Mihm, A. Berns, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Genomic Profiling Reveals Differences in Primary Central Nervous System Lymphoma and Large B-Cell Lymphoma, With Subtyping Suggesting Sensitivity to BTK Inhibition

P. Hegde, R. Strowd, E. Severson, 2022, The oncologist.